Preferred Label : romosozumab;
MeSH note : an anti-sclerostin agent for treatment of osteoporosis; in phase II clincal trials
(2011);
MeSH hyponym : CDP7851; CDP-7851; AMG785; AMG-785; romosozumab-aqqg;
Is substance : O;
UNII : 3VHF2ZD92J;
Origin ID : C557282;
UMLS CUI : C3661283;
ATC code(s)
Currated CISMeF NLP mapping
MeSH term(s) associated for indexing
Record concept(s)
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
https://www.has-sante.fr/jcms/p_3243905/fr/evenity
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
romosozumab
guidelines for drug use
osteoporosis, postmenopausal
osteoporotic fractures
aged
risk assessment
injections, subcutaneous
evenity
Product containing only romosozumab in parenteral dose form (medicinal product form)
evaluation of the transparency committee
romosozumab
romosozumab
antibodies, monoclonal
antibodies, monoclonal
---
https://www.ema.europa.eu/en/medicines/human/EPAR/evenity
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
romosozumab
osteoporotic fractures
osteoporosis, postmenopausal
adult
aged
injections, subcutaneous
SOST protein, human
product surveillance, postmarketing
pregnancy
breast feeding
drug evaluation, preclinical
evenity
Product containing only romosozumab in parenteral dose form (medicinal product form)
romosozumab
romosozumab
antibodies, monoclonal
antibodies, monoclonal
genetic markers
bone morphogenetic proteins
---
https://pharmactuel.com/index.php/pharmactuel/article/view/1250
2019
false
false
false
false
Canada
critical appraisal or critical reading
bone density conservation agents
osteoporosis, postmenopausal
alendronate
bone density conservation agents
spinal fractures
spinal fractures
journal article
alendronate
osteoporotic fractures
female
romosozumab
antibodies, monoclonal
romosozumab
antibodies, monoclonal
---
https://www.pharmactuel.com/index.php/pharmactuel/article/view/1198
2018
false
false
false
Canada
French
SOST protein, human
osteoporotic fractures
hip fractures
spinal fractures
treatment outcome
critical appraisal or critical reading
romosozumab
osteoporosis, postmenopausal
romosozumab
antibodies, monoclonal
romosozumab
genetic markers
bone morphogenetic proteins
antibodies, monoclonal
---